Phase 3 N=188 Confirmatory Study of OPC-12759 Ophthalmic Suspension
Dry Eye Syndromes
Primary: Change in Fluorescein Corneal Staining (FCS) Score From Baseline — -3.7; -2.9 units on a scale — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=6 Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age
Anesthesia
Primary: Percent of Subjects Requiring Rescue Midazolam for Sedation — 0 percentage of participants
Phase 3 N=137 Insomnia and Drug Relapse Risk
Poor Quality Sleep · Opiate Addiction
Primary: Sleep Quality, as Measured by Total Sleep Time — 339; 329 minutes — p=.05
Phase 3 N=66 Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
Hodgkin Disease · Non-Hodgkin Lymphoma · Multiple Myeloma
Primary: Incidence of Clinically Significant Bacteremia — 3; 9 participants
Phase 3 N=2,858 A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy
Contraception · Female Contraception
Primary: All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight, Using the 7-Day Rule…
Phase 3 N=861 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Metastatic Pancreatic Cancer
Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001
Phase 3 N=323 Mycotic Ulcer Treatment Trial I
Corneal Ulcer · Eye Infections, Fungal
Primary: Best Spectacle-corrected logMAR Visual Acuity — 0.39; 0.57 logMAR — p=0.006
Phase 3 N=38 A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection
Intra-abdominal Infections
Primary: Clinical Response: Response Rate (Data Review Committee Assessment) — 96.6; 96.7 percentage of participants
Phase 3 N=379 Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants With Seroprotection to Hepatitis H Antigen After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) or…
Phase 3 N=549 Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa
Acute Otitis Externa
Primary: Proportion of Patients With Clinical Cures at the Day 11 (TOC) Visit — 68.7; 40.0 Percentage of participants
Phase 3 N=72 Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty
Precocious · Leuprolide Acetate · Luteinizing Hormone (LH)
Primary: Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone — 96.9; 100.0; 93.8; 100.0 percentage of participants
Phase 3 N=417 Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Thyroid Neoplasms
Primary: Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation — 329; 175 Days — p=<0.0001
Phase 3 N=352 Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia
Anemia
Primary: Number of Subjects Who Achieved 'Success' Meaning a ≥ 2.0 Increase in Hemoglobin — 162; 159 participants
Phase 3 N=183 A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients
Hepatitis C, Chronic
Primary: The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 12 Weeks After the Last Dose of Treatment (SVR12) — 88.6; 61.7…
Phase 3 N=420 TAASS-Traumeel Ointment and Gel Compared With a Topical NSAID in Athletes With Acute Ankle Sprain
Sprain of Ankle
Primary: Patient's Assessment of Ankle Pain (VAS)- Absolute Value Decrease on Day 7 — -33.00; -37.10; -37.10 Absolute value units on a scale VAS